Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

Inclusion Criteria: * Patients must have histological confirmation of Solid Tumor or Lymphoma that is metastatic or unresectable; if assessing a single target lesion, histological confirmation of that particular lesion MUST be carried out * Patients may have received an unlimited number of prior therapies; however, At least 4 weeks MUST have passed since the last chemotherapy to day 1 of registration (6 weeks for regimens containing nitrosoureas or Mitomycin C) * ECOG performance status =\< 2 (Karnofsky \>= 60%) * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Total bilirubin =\< 2.0 mg/dL (does NOT apply to patients with Gilbert's Syndrome) * AST(SGOT)/ALT(SGPT) =\< 2.5 X institutional upper limit of normal (Patients with liver involvement will be allowed =\< 5.0 X institutional upper normal limit) * Serum creatinine =\< 2.0 mg/dL * Patients MUST have recovered from all treatment related toxicities to Grade 1 NCI CTC (v 4.0) in severity * Patients must be willing and able to review, understand, and provide written consent before starting therapy * Patients with stable brain metastasis (stable disease on one MRI assessment at least 4 weeks after completion of whole brain radiation, no evidence of progression on MRI assessment 4 weeks after stereotactic radiosurgery or complete surgical excision) will also be allowed to participate in this trial * Patients with histologically proven intracranial glioblastoma, gliosarcoma or an…